SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 74 of 94
Word Count: 1423
Character Count: 8850

Document Content:

to include the information required of a disclosure document for the purposes of the Corporations Act; and ● may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. The securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any securities may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities, you represent and warrant to us that you are an Exempt Investor.

any offer of securities under this prospectus will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act,
the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure
to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the securities you undertake
to us that you will not, for a period of 12 months from the date of issue of the securities, offer, transfer, assign or otherwise alienate
those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of
the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.

Canada

The
securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients,
as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws.

Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars
of these rights or consult with a legal advisor.

Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.

European
Economic Area

relation to each Member State of the European Economic Area and the United Kingdom, or each a Relevant State, no securities have been
offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in
relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved
in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation,
except that offers of securities may be made to the public in that Relevant State at any time under the following exemptions under the
Prospectus Regulation:

any legal entity which is a qualified investor as defined under the Prospectus Regulation;

fewer than 150 natural or legal persons (other than qualified investors as defined under
the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or

any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided
that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any
securities or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters
and us that it is a “qualified investor” within the meaning of Article 2(e) of the Prospectus Regulation. In the case of
any securities being offered to a financial intermediary as that term is used Prospectus Regulation, each such financial intermediary
will be deemed to have represented, acknowledged and agreed that the securities acquired by it in the offer have not been acquired on
a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant State to qualified investors
as so defined or in circumstances in which the prior consent of the Representative has been obtained to each such proposed offer or resale.

For
the purposes of this provision, the expression an “offer to the public” in relation to securities in any Relevant State means
the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so
as to enable an investor to decide to purchase or subscribe for any securities, and the expression “Prospectus Regulation”
means Regulation (EU) 2017/1129.

Hong
Kong

The
securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional
investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and
any rules made thereunder; or (b) in other circumstances which do not result in the document being a “prospectus” as defined
in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an
offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the securities has been or may
be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under
the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside
Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder.

Israel

This
prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the
Israel Securities Authority. In Israel, this prospectus may be distributed only to, and is directed only at, investors listed in the
first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds; provident funds;
insurance companies; banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange Ltd., underwriters, each
purchasing for their own account; venture capital funds; entities with equity in excess of NIS 50 million and “qualified individuals,”
each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors. Qualified
investors shall be required to submit written confirmation that they fall within the scope of the Addendum.

Japan

The
securities have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act.
Accordingly, none of the securities nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the
benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation
or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or
for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance
with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect
at the relevant time.

Singapore